Adlai Nortye Biopharma Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adlai Nortye Biopharma Co., Ltd.
Asia Deal Watch: SV Investment And Orange Grove Will Team Up On New Company Effort
Takeda spins out Oak Hill Bio, Lupin and Axantia will co-develop filgrastim biosimilar and Xbiome licenses skin ulcer candidate from Aurealis.
Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.
Finance Watch: $135m In Venture Capital Will Fund Amylyx’s Late-Stage ALS Drug
Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.
Chinese Bioventures Grab $860m In Latest Public Listing, Financing Dash
Accelerated initial public listings, multi-million dollar deals and hot investment fund influxes fuel an already record-setting July for biotech fundraising in China.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.